About Artiva Biotherapeutics
We are dedicated to making safe and effective cell therapies accessible to any cancer patient who may benefit.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Founded
- 2019
- Company type
- Privately Held
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
Specialties
- cell therapy
- cancer
- nk cells
- nk cell therapy
- and car-nk
Company locations
5505 Morehouse Drive, Suite 100, San Diego, California 92121, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biotechnology
- Life Science
- Therapeutics
On LinkedIn
- Followers
- 14,455
- People linked to this company
- 108
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
498,000,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.